Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: A computer-implemented method includes obtaining a first set of trip data associated with a first set of vehicular trips operated by a vehicle operator during a first time period. The first set of trip data includes a first set of telematics data and a first set of travel conditions. The method also includes determining a second set of travel conditions associated with a target vehicular trip. The method further includes predicting a second set of telematics data associated with the target vehicular trip. The method further includes determining a set of vehicle operation behaviors based at least in part on the second set of telematics data, as predicted. Other embodiments are disclosed.

Abstract: Method, system, device, and non-transitory computer-readable medium for adjusting a dynamic discount. In one aspect, a computer-implemented method includes: receiving an enrollment request from a user associated with a vehicle for a vehicle insurance policy; issuing an initial discount to the user for the vehicle insurance policy at a first time; collecting trip data associated with a set of vehicular trips operated by the user with the vehicle, the trip data including telematics data and travel condition data; and dynamically updating the initial discount based at least in part upon the trip data as trip data are collected.

Abstract: Method, system, device, and non-transitory computer-readable medium for predicting trip data. In one aspect, a computer-implemented method includes: obtaining a first set of trip data associated with a first set of vehicular trips operated by a vehicle operator during a first time period, the first set of trip data including a first set of telematics data and a first set of travel conditions; obtaining a second set of travel conditions associated with a second set of vehicular trips associated with a second time period separate from the first time period; and determining a second set of telematics data associated with a target vehicular trip based at least in part upon the first set of telematics data, the first set of travel conditions, and the second set of travel conditions.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: Method, system, device, and non-transitory computer-readable medium for predicting trip data. In one aspect, a computer-implemented method includes: obtaining a first set of trip data associated with a first set of vehicular trips operated by a vehicle operator during a first time period, the first set of trip data including a first set of telematics data and a first set of travel conditions; obtaining a second set of travel conditions associated with a second set of vehicular trips associated with a second time period separate from the first time period; and determining a second set of telematics data associated with a target vehicular trip based at least in part upon the first set of telematics data, the first set of travel conditions, and the second set of travel conditions.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: Method, system, device, and non-transitory computer-readable medium for adjusting a dynamic discount. In one aspect, a computer-implemented method includes: receiving an enrollment request from a user associated with a vehicle for a vehicle insurance policy; issuing an initial discount to the user for the vehicle insurance policy at a first time; collecting trip data associated with a set of vehicular trips operated by the user with the vehicle, the trip data including telematics data and travel condition data; and dynamically updating the initial discount based at least in part upon the trip data as trip data are collected.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.